{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "KRW", "marketState": "PREPRE", "regularMarketChangePercent": 0.1283697, "regularMarketPrice": 78000.0, "exchange": "KSC", "shortName": "SKBS", "longName": "SK bioscience Co.,Ltd.", "messageBoardId": "finmb_574494123", "exchangeTimezoneName": "Asia/Seoul", "exchangeTimezoneShortName": "KST", "gmtOffSetMilliseconds": 32400000, "market": "kr_market", "esgPopulated": false, "regularMarketTime": 1683873029, "earningsTimestamp": 1683889140, "earningsTimestampStart": 1691665140, "earningsTimestampEnd": 1692014400, "epsCurrentYear": 688.87, "priceEpsCurrentYear": 113.22891, "sharesOutstanding": 76784000, "fiftyDayAverage": 73232.0, "fiftyDayAverageChange": 4768.0, "fiftyDayAverageChangePercent": 0.06510815, "twoHundredDayAverage": 84385.0, "twoHundredDayAverageChange": -6385.0, "twoHundredDayAverageChangePercent": -0.07566511, "marketCap": 5989152063488, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "3.1 - Hold", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1616025600000, "priceHint": 2, "regularMarketChange": 100.0, "regularMarketDayHigh": 79900.0, "regularMarketDayRange": "77300.0 - 79900.0", "regularMarketDayLow": 77300.0, "regularMarketVolume": 293277, "regularMarketPreviousClose": 77900.0, "bid": 77900.0, "ask": 78000.0, "fullExchangeName": "KSE", "financialCurrency": "KRW", "regularMarketOpen": 78600.0, "averageDailyVolume3Month": 386711, "averageDailyVolume10Day": 805531, "fiftyTwoWeekLowChange": 12800.0, "fiftyTwoWeekLowChangePercent": 0.19631901, "fiftyTwoWeekRange": "65200.0 - 156500.0", "fiftyTwoWeekHighChange": -78500.0, "fiftyTwoWeekHighChangePercent": -0.50159746, "fiftyTwoWeekLow": 65200.0, "fiftyTwoWeekHigh": 156500.0, "symbol": "302440.KS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "310, Pangyo-ro", "address2": "Bundang-gu", "city": "Seongnam-si", "zip": "13494", "country": "South Korea", "phone": "82 2 2008 2200", "fax": "82 2 2008 2969", "website": "https://www.skbioscience.co.kr", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jae-Yong  Ahn", "age": 55, "title": "CEO, Pres & Director", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Hoon  Kim", "age": 55, "title": "CTO & Exec. Director", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Harry  Kleanthous", "title": "Exec. VP of Vaccine R&D Strategy & External Innovation", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sally  Choe", "title": "Head of Global Clinical Devel. & Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}